← Back to Screener
Bristol-Myers Squibb Co. (BMY)
Price$60.17
Favorite Metrics
Price vs S&P 500 (26W)28.13%
Price vs S&P 500 (4W)-4.81%
Market Capitalization$122.85B
P/E Ratio (Annual)17.42x
Indicated Dividend Yield (Annual)4.27%
All Metrics
P/CF (Annual)8.68x
Book Value / Share (Quarterly)$9.18
P/TBV (Annual)44.28x
Indicated Dividend (Annual)$2.48
Revenue Growth (3Y)1.45%
Cash Flow / Share (Quarterly)$6.38
Payout Ratio (TTM)71.51%
Price vs S&P 500 (YTD)7.41%
Gross Margin (TTM)72.63%
Net Profit Margin (TTM)14.64%
EPS (TTM)$3.46
10-Day Avg Trading Volume8.98M
EPS Excl Extra (TTM)$3.46
Revenue Growth (5Y)2.54%
EPS (Annual)$3.46
Dividend / Share (Annual)$2.51
ROI (Annual)11.09%
Gross Margin (Annual)72.62%
Net Profit Margin (5Y Avg)8.55%
Cash / Share (Quarterly)$5.30
P/E Basic Excl Extra (TTM)17.41x
Revenue Growth QoQ (YoY)1.30%
P/E Normalized (Annual)17.42x
ROA (Last FY)7.83%
Revenue Growth TTM (YoY)-0.22%
EBITD / Share (TTM)$6.70
ROE (5Y Avg)10.10%
Operating Margin (TTM)21.51%
Cash Flow / Share (Annual)$6.38
P/B Ratio6.65x
P/B Ratio (Quarterly)5.94x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.27x
Net Interest Coverage (TTM)10.10x
ROA (TTM)7.54%
EPS Growth QoQ (YoY)1401.69%
EV / EBITDA (TTM)11.54x
EPS Incl Extra (Annual)$3.46
Current Ratio (Annual)1.26x
Quick Ratio (Quarterly)1.14x
3-Month Avg Trading Volume13.44M
52-Week Price Return21.90%
EV / Free Cash Flow (Annual)12.28x
P/E Incl Extra (TTM)17.41x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.17
P/S Ratio (Annual)2.55x
Asset Turnover (Annual)0.54x
52-Week High$62.89
Operating Margin (5Y Avg)13.60%
EPS Excl Extra (Annual)$3.46
CapEx CAGR (5Y)11.73%
Tangible BV CAGR (5Y)-29.03%
26-Week Price Return36.87%
Quick Ratio (Annual)1.14x
13-Week Price Return5.52%
Total Debt / Equity (Annual)2.44x
Current Ratio (Quarterly)1.26x
Enterprise Value$157,753.22
Revenue / Share Growth (5Y)4.65%
Asset Turnover (TTM)0.52x
Book Value / Share Growth (5Y)-11.63%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)5.03x
Pretax Margin (Annual)19.36%
Cash / Share (Annual)$5.30
3-Month Return Std Dev25.25%
Gross Margin (5Y Avg)76.36%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)36.47%
ROE (Last FY)38.19%
Net Interest Coverage (Annual)10.10x
EPS Basic Excl Extra (Annual)$3.46
P/FCF (TTM)9.56x
Receivables Turnover (TTM)5.02x
EV / Free Cash Flow (TTM)12.28x
Total Debt / Equity (Quarterly)2.44x
EPS Incl Extra (TTM)$3.46
Receivables Turnover (Annual)5.02x
ROI (TTM)10.66%
Dividend Growth Rate (5Y)6.51%
P/S Ratio (TTM)2.55x
Pretax Margin (5Y Avg)10.99%
Revenue / Share (Annual)$23.64
Tangible BV / Share (Annual)$1.17
Forward P/E9.60x
Free OCF CAGR (5Y)-0.69%
Price vs S&P 500 (52W)-13.19%
P/E Ratio (TTM)17.41x
Year-to-Date Return11.55%
5-Day Price Return3.63%
EPS Normalized (Annual)$3.46
ROA (5Y Avg)3.91%
Net Profit Margin (Annual)14.64%
Month-to-Date Return-0.79%
Cash Flow / Share (TTM)$8.63
EBITD / Share (Annual)$6.70
EPS Growth (3Y)5.47%
Operating Margin (Annual)21.50%
LT Debt / Equity (Annual)2.32x
P/CF (TTM)8.68x
ROI (5Y Avg)5.36%
P/E Excl Extra (TTM)17.41x
LT Debt / Equity (Quarterly)2.32x
EPS Basic Excl Extra (TTM)$3.46
P/TBV (Quarterly)44.28x
Payout Ratio (Annual)71.52%
P/B Ratio (Annual)5.94x
Dividend / Share (TTM)$2.51
Inventory Turnover (TTM)5.03x
Pretax Margin (TTM)19.36%
Book Value / Share (Annual)$9.18
Price vs S&P 500 (13W)2.66%
Dividend Yield (TTM)4.11%
Beta0.26x
P/FCF (Annual)9.56x
Revenue / Share (TTM)$23.64
ROE (TTM)39.28%
52-Week Low$42.52
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.50
3.53
3.53
3.53
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 2.60x | 4.11% | 72.67% | -0.54% | $58.35 |
About
Bristol Myers Squibb is a biopharmaceutical company with leading capabilities in immuno-oncology and a broad portfolio spanning cardiovascular, oncology, and immunology therapies. The company is heavily concentrated in the US market, which accounts for approximately 70% of revenues—above the industry average.